Table 3.
Application of aptamers in clinical trials to cancer therapy
| Aptamer name | Study title | Target | Intervention/treatment | Phase | NCT number | Type of cancer |
|---|---|---|---|---|---|---|
| AS1411 | A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia | Nucleolin |
Drug: AS1411 Drug: Cytarabine |
Phase 2 | NCT01034410 | Acute Myeloid Leukemia |
| Study of AS1411 in Advanced Solid Tumours | Drug: AS1411 | Phase 1 | NCT00881244 | Advanced Solid Tumors | ||
| A Phase II Study of AS1411 in Renal Cell Carcinoma | Drug: AS1411 | Phase 2 | NCT00740441 | Metastatic Renal Cell Carcinoma | ||
| Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia | Drug: AS1411 | Phase 2 | NCT00512083 | Leukemia, Myeloid | ||
| EYE001 | EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | VEGF | Drug: EYE001 | Phase 1 | NCT00056199 | Hippel–Lindau disease |
| Olaptesed Pegol (NOX-A12) | Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (Keynote-559) | CXCL12/SDF-1 |
Drug: Olaptesed pegol—Monotherapy Drug: Olaptesed pegol + Pembrolizumab—Combination Therapy |
Phase 2 | NCT03168139 | Metastatic Colorectal Cancer Metastatic Pancreatic Cancer |
| Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer (OPTIMUS) | Drug: Olaptesed pegol | Phase 2 | NCT04901741 | Metastatic Pancreatic Cancer | ||
| NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma | Drug: NOX-A12 | Phase 2 | NCT01521533 | Multiple Myeloma | ||
| Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients (GLORIA) |
Drug: Olaptesed pegol Radiation: Radiotherapy Drug: Bevacizumab Drug: Pembrolizumab |
Phase 2 | NCT04121455 | Glioblastoma | ||
| NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) | CXCR4-CXCL12 | Drug: NOX-A12 | Phase 2 | NCT01486797 | Chronic Lymphocytic Leukemia | |
| Lexaptepid Pegol (NOX-H94) | Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer | Hepcidin | Drug: NOX-H94 | Phase 2 | NCT01691040 | Anemia of Chronic Disease |